Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Statement re Offer Approaches

12 Sep 2011 11:36

RNS Number : 0512O
Evolution Group PLC
12 September 2011
 



The Evolution Group PLC

12 September 2011

The Evolution Group plc ("Evolution")

Statement regarding Offer Approaches

On 16 August 2011, The Evolution Group Plc ("Evolution") announced, amongst other things, that the Board had received approaches from a number of parties, in addition to the approach from Investec plc ("Investec"), who were interested in either part or the whole of the Company.

On 8 September 2011, Canaccord Financial Inc. announced that it will not proceed with an offer and will be bound by Rule 2.8 of the City Code on Takeover and Mergers (the "Code").

On 9 September 2011, Investec announced a recommended share offer for Evolution under Rule 2.5 of the Code. The Board of Evolution confirms that discussions with all parties other than Investec have now ceased.

 

-END-

 

Enquiries:

The Evolution Group Plc Tel: 020 7071 4300

Alex Snow, CEO, The Evolution Group PLC

 

Pelham Bell Pottinger Tel: 020 7861 3925

Victoria Geoghegan

 

The directors of Evolution accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDGGURPBUPGGUP
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.